Celltrion USA announced today that adalimumab-aaty, the company’s high-concentration (100 mg/mL) and citrate-free formulation biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost (WAC).
Adalimumab-aaty will be priced as WAC list price at an 85% discount to the current WAC list price of Humira. Adalimumab-aaty is also available from Celltrion USA under the brand name Yuflyma, which launched in July 2023 and is available at a 5% discount to the current WAC list price of Humira.
Adalimumab-aaty is approved for the treatment of eight conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
“Access to medications in the U.S. has become increasingly complex, and there is so much value that biosimilars add with competition in the marketplace,” says Thomas Nusbickel, Chief Commercial Officer at Celltrion USA, in a news release. “The availability of branded and unbranded versions of adalimumab-aaty will improve the accessibility of adalimumab biosimilars in the U.S., providing economic benefits for patients and the overall healthcare system.”
Adalimumab-aaty is available as 40 mg/0.4mL, 80 mg/0.8mL and 20 mg/0.2mL.
